| pubmed-article:19297314 | pubmed:abstractText | This randomized, phase II study assessed the activity of oblimersen sodium, a Bcl-2 antisense oligonucleotide, administered before docetaxel (Taxotere) to patients with castration-resistant prostate cancer. | lld:pubmed |
